ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
IPO Year: 2020
Exchange: NASDAQ
Website: aditxt.com
4 - Aditxt, Inc. (0001726711) (Issuer)
3 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic
Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis. The study, "Mitochondrial DNA Deletions in Plasma as a D
Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune's Lead Therapeutic Candidate for Autoimmune Diseases Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that a recently completed study conducted by the Mayo Clinic further validates the preclinical findings of ADI-100, the lead therapeutic candidate developed by Aditxt's wholly owned subsidiary, Adimune™, Inc. ("Adimune"). The independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic's neuroimmunology team, confirmed that ADI-100 induces immune tolerance to glutamic acid decarboxy
The event will begin today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that today's Aditxt Weekly Update will provide key updates on recent events, including: Aditxt's recent notice from Nasdaq that it had regained compliance with Nasdaq's minimum bid price requirement and is therefore in compliance with the Nasdaq Capital Market's listing requirements Updates on the Company's operating subsidiaries Progress on strategic transactions currently underway Event Details: Title: Aditxt Weekly Update Date: Friday, April 11, 2025 Time: 11:30 a.m. ET Location: Virtual (Zoom) Regis
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel scheduled to take place on April 22, 2025, has been cancelled. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol ADTX. "We are pleased to have regained compliance with Nasdaq's listing requirements. We continue to remain focus
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in
Event exploring the increasing risk of emerging infectious diseases Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatm
The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University Aditxt, Inc. (NASDAQ:ADTX), ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that today's Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. ("Pearsanta"). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and othe
-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E
Acquisition is key to Pearsanta's mission of addressing cancer through early detection and prevention Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA/CAP-certified monitoring center and laboratories Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry. Pearsanta acquired the patents in exch
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
424B5 - Aditxt, Inc. (0001726711) (Filer)
424B5 - Aditxt, Inc. (0001726711) (Filer)
Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.'s ("Evofem") (OTCQB:EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substit
SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe
This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women's health, spanning endometriosis to ovarian cancer, and in men's health starting with prostate cancer Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired MDNA Life Sciences Inc.'s ("MDNA") proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta's dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. Th
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in
Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the Company along with its partners, have submitted applications for four new federal funding opportunities. The funding, if awarded, would total up to US$117.5 million and support the company's
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as
Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company's wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie's appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business ("B2B") and direct-to-consumer ("DTC") clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. "Naming Ernie as
AditxtScore™ continued driving revenue growth in 2022 by adding to its expanding customer base of large physician networks, healthcare systems, independent laboratories, and employer-sponsored programs. Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt's second program, AditxtScore™, through future strategic revenue and growth-oriented transactions. Anthony Voorhies, currently the head of the AditxtScore™ division, will s
Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for ty
Aditxt, Inc. ("Aditxt, or the "Company"). (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal Accounting Officer of Aditxt, has been appointed as CFO. As CFO of Aditxt since July 2020, Ms. Pankovcin, along with the Company's CEO and executive team, has effectively managed the Company's growth as it became publicly traded on
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. "As a new independent director of Aditxt's board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals," said Amro Albanna, co-founder and CEO of Aditxt. "We look forward to working with Dr. Chung as we establish our portfolio of fi